CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $248.05M, lower than 95% of all stocks globally
- PositionOperating margin is -36426.9%, lower than 95% of its Biotechnology peers (median -38%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
38.91BJPY248.05M · vs all stocks (USD)
Trailing P/E
322.67xvs Biotechnology peers
Revenue (TTM)
3.03BJPY19.29M · vs all stocks (USD)
Profit Margin
19.58%vs Biotechnology peers
Beta
-0.7870xvs all stocks
52-Week Change
-26.57%vs all stocks
Market Capitalization
38.91BJPY248.05M · vs all stocks (USD)
Enterprise Value
54.61BJPY348.12M · vs all stocks (USD)
Trailing P/E
322.67xvs Biotechnology peers
Forward P/E
-24.21xvs Biotechnology peers
Price to Sales (TTM)
20.14xvs Biotechnology peers
Price to Book (MRQ)
9.15xvs Biotechnology peers
Enterprise to Revenue
18.04xvs Biotechnology peers
Enterprise to EBITDA
71.08xvs Biotechnology peers
Profit Margin
19.58%vs Biotechnology peers
Return on Assets (TTM)
5.97%vs Biotechnology peers
Return on Equity (TTM)
8.35%vs Biotechnology peers
Revenue (TTM)
3.03BJPY19.29M · vs all stocks (USD)
Revenue per Share (TTM)
134.24JPYUpdated Sep 20, 2026Gross Profit (TTM)
3.03BJPY19.29M · vs all stocks (USD)
EBITDA (TTM)
342.15MJPY2.18M · vs all stocks (USD)
Net Income (TTM)
592.50MJPY3.78M · vs all stocks (USD)
Operating Cash Flow (TTM)
1.08BJPY6.89M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
190.61MJPY1.22M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00JPYUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.03BJPYFY2025 · Oct 31, 2025Cost of Goods Sold
0.00JPYFY2025 · Oct 31, 2025Gross Profit
3.03BJPYFY2025 · Oct 31, 2025Operating Income
272.16MJPY1.74M · vs all stocks (USD)
Pre-tax Income
288.99MJPYFY2025 · Oct 31, 2025Income Tax Expense
98.38MJPYFY2025 · Oct 31, 2025Net Income
190.61MJPYFY2025 · Oct 31, 2025EBIT
289.14MJPYFY2025 · Oct 31, 2025EBITDA (Income Statement)
342.15MJPYFY2025 · Oct 31, 2025Non-operating Interest Income
5.92MJPYFY2025 · Oct 31, 2025Non-operating Interest Expense
159.00KJPYFY2025 · Oct 31, 2025Preferred Stock Dividends
0.00JPYFY2025 · Oct 31, 2025Operating Cash Flow
973.13MJPYFY2025 · Oct 31, 2025Free Cash Flow
944.45MJPYFY2025 · Oct 31, 2025Cash & Cash Equivalents (End of Period)
6.84BJPYFY2025 · Oct 31, 2025Starting Profit (CF Statement)
288.99MJPYFY2025 · Oct 31, 2025Other Non-cash Items
-97.28MJPYFY2025 · Oct 31, 2025Change in Accounts Receivable (CF)
749.46MJPYFY2025 · Oct 31, 2025Change in Other Assets/Liabilities
31.97MJPYFY2025 · Oct 31, 2025Capital Expenditures
-28.69MJPYFY2025 · Oct 31, 2025Other Investing Activity
101.32MJPYFY2025 · Oct 31, 2025Net Investing Cash Flow
72.64MJPYFY2025 · Oct 31, 2025Other Financing Charges
-1.00KJPYFY2025 · Oct 31, 2025Net Financing Cash Flow
381.05MJPYFY2025 · Oct 31, 2025Shares Outstanding
22.87MSharesUpdated Sep 20, 2026Float Shares
9.49MSharesUpdated Sep 20, 2026% Held by Insiders
46.03%vs all stocks
% Held by Institutions
2.30%vs all stocks
Total Cash (MRQ)
6.34BJPY40.39M · vs all stocks (USD)
Total Cash per Share (MRQ)
276.74JPYUpdated Sep 20, 2026Total Debt (MRQ)
0.00JPYvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
18.48xvs Biotechnology peers
Book Value per Share (MRQ)
291.05JPYUpdated Sep 20, 2026Total Assets
7.68BJPY48.93M · vs all stocks (USD)
Total Current Assets
7.14BJPYFY2025 · Oct 31, 2025Total Liabilities
480.84MJPYFY2025 · Oct 31, 2025Total Non-current Assets
532.21MJPYFY2025 · Oct 31, 2025Total Non-current Liabilities
160.51MJPYFY2025 · Oct 31, 2025Total Current Liabilities
320.33MJPYFY2025 · Oct 31, 2025Cash & Cash Equivalents
6.84BJPYFY2025 · Oct 31, 2025Accounts Receivable
0.00JPYFY2025 · Oct 31, 2025Inventory
47.87MJPYFY2025 · Oct 31, 2025Short-term Debt
252.00KJPYFY2025 · Oct 31, 2025Other Current Liabilities
8.60MJPYFY2025 · Oct 31, 2025Long-term Debt
0.00JPYFY2025 · Oct 31, 2025Other Non-current Liabilities
2.00KJPYFY2025 · Oct 31, 2025Common Stock (Book)
1.33BJPYFY2025 · Oct 31, 2025Retained Earnings
-2.58BJPYFY2025 · Oct 31, 2025Total Shareholders' Equity
7.19BJPY45.87M · vs all stocks (USD)
52-Week Low
1.34KJPYUpdated Sep 20, 202652-Week High
3.80KJPYUpdated Sep 20, 202652-Week Change
-26.57%vs all stocks
Beta
-0.7870xvs all stocks
50-Day MA
2.01KJPYUpdated Sep 20, 2026200-Day MA
1.86KJPYUpdated Sep 20, 2026Avg 10-Day Volume
435.02KSharesUpdated Sep 20, 2026Avg 30-Day Volume
486.58KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
8.25JPYUpdated Sep 20, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -36426.9%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -364.269Industry median: -0.38Industry P5: -43.63Peers compared: 260
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $248.05M, lower than 95% of all stocks globallySignificant
Market cap (USD): 248,048,990.7Global P5: 275,556,405.438
Revenue is $19.29M, lower than 95% of all stocks globallySignificant
Revenue (USD): 19,293,938.112Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Acimmune SA
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
United States Lime & Minerals Inc.
4 interpretationsCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
Vicor Corporation
4 interpretationsCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
Nien Made Enterprise Co., Ltd.
4 interpretationsCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated